ArticleMethodsX2026
Flow cytometry method to identify arginase-1 expressing MDSCs.
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Myeloid-derived suppressor cells (MDSCs) contribute to immune suppression in cancer through arginase-1 (ARG1), which limits T-cell activation. Conventional assays such as ELISA or qPCR cannot determine the cellular source of ARG1 in blood. Recognizing the importance of ARG1 in immunosuppression, we developed and validated a standardized flow cytometry method using a commercially available ARG1 antibody to measure intracellular ARG1 in MDSC subsets. This method includes detailed instructions, including experimental optimization using positive and negative controls, to help other researchers perform flow cytometric measurement of ARG1 expressing cells. In this method, peripheral blood mononuclear cells were stained for lymphoid and myeloid markers (CD3, CD20, CD56, HLA-DR, CD33, CD11b, CD14, and CD15), fixed, and permeabilized before intracellular ARG1 staining. Antibody specificity was verified using neutrophils as positive and CD4⁺ T cells as negative controls. The method was applied to blood samples from patients with bladder cancer (n = 23) and healthy volunteers (n = 10), demonstrating reliable detection of intracellular ARG1 in MDSC subpopulations. This accessible protocol provides an adaptable method for quantifying cell-specific ARG1 expression and studying MDSC-mediated immunosuppression.•The flow cytometry method described here was developed by validating the arginase1 antibody binding specificity using cells expressing high and very low levels of arginase-1.•Arginase-1-expressing cells of the peripheral blood monocytes were identified using this method.•This method can be adapted to any cell type and will be a valuable tool in future immunosuppression studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.